{"preliminary_commentary":{"by_channel":{"x_thread":9},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT06256328\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":{"generated_at":"2026-11-22T14:53:32.780Z","note":"Automated from all 9 indexed sources (Apr 2026 – Jun 2026). Each question is raised in at least two. Not an Erudio report: no source links. Not medical advice.","passages_read":9,"text":"- Whether the effect of adding ONO-4578 differs by PD-L1 CPS, and which cutoff defines who might benefit\n- Whether adding ONO-4578 to nivolumab plus chemotherapy delays progression compared with placebo\n- Whether ONO-4578 improves overall survival once follow-up matures\n- Whether adding ONO-4578 changes the serious adverse event burden of nivolumab plus chemotherapy","kind":"questions"},"drugs_tested":[["ONO-4578","nivolumab"]],"indication":"chemotherapy-naïve HER2-negative unresectable advanced or recurrent gastric cancer","name":"ONO-4578-08","nct_id":"NCT06256328","offer":{"currency":"USD","how":"Buy the first edition with create_order on https://mcp.erudio.com/mcp (product \"first_edition\", report \"NCT06256328\", the buyer's work email and organization), or POST https://www.erudio.com/api/orders with the same fields. It returns a Stripe checkout_url for your person to pay by card; a first edition has no agent-wallet payment. The person can also order on https://www.erudio.com/trials/ono-4578-08-nct06256328. We build the first edition within 24 hours of payment and email it to you once it passes our checks and review. If your report can't be delivered, we'll contact you and refund it in full.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":750,"product":"first_edition","size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":null,"label":"ONO-4578+Nivolumab+chemotherapy","type":"EXPERIMENTAL"},{"description":null,"label":"placebo+Nivolumab+chemotherapy","type":"PLACEBO_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-07-31","type":"ESTIMATED"},"conditions":["Gastric Cancer"],"enrollment":{"count":226,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"ONO-4578","otherNames":[],"type":"DRUG"},{"name":"Oxaliplatin","otherNames":[],"type":"DRUG"},{"name":"Capecitabine","otherNames":[],"type":"DRUG"},{"name":"S-1","otherNames":["Tegafur-gimeracil-oteracil potassium"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["Opdivo"],"type":"DRUG"},{"name":"Placebo","otherNames":[],"type":"DRUG"}],"last_update":"2026-03-13","lead_sponsor":"Ono Pharmaceutical Co., Ltd.","official_title":"A Randomized, Multicenter, Double-blind, Phase II Study to Compare the Efficacy and Safety of the Treatment With ONO-4578 in Combination With Nivolumab, Fluoropyrimidine-based and Platinum- Based Chemotherapy (Hereinafter Referred to as Chemotherapy) With Those of the Treatment With Placebo in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE2"],"primary_completion_date":{"date":"2025-10-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-free survival (PFS) (site investigator assessment)","timeFrame":"up to 2years"}],"references":[{"citation":"Nakayama I, Ryu MH, Lim SH, Kim JG, Omori T, Oh SC, Kim JY, Rha SY, Lee KW, Machida N, Sym SJ, Narita Y, Park YI, Hara H, Hosaka H, Kang B, Kim IH, Bai LY, Hirashima Y, Hagihara S, Yamamoto T, Shitara K. EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer. J Clin Oncol. 2026 Aug 10;44(23):2198-2210. doi: 10.1200/JCO-26-01072. Epub 2026 Jun 1.","pmid":"42223130","type":"DERIVED"}],"start_date":{"date":"2024-01-10","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","url":"https://clinicaltrials.gov/study/NCT06256328"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/ono-4578-08-nct06256328"}